Navigation Links
Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
Date:4/30/2008

WALTHAM, Mass., April 30 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), today announced that it has appointed Eliot M. Lurier, CPA, as its Chief Financial Officer.

Lewis H. Bender, Chief Executive Officer of Interleukin Genetics, Inc., commented on the appointment, "Eliot is an innovative and experienced senior financial executive with an entrepreneurial spirit and a proven record of achievement in managing growth for publicly traded companies. The addition of Eliot to the senior management team provides financial management and operational skills that we need to develop and grow our business."

Mr. Lurier, age 50, has more than 25 years of financial management experience, primarily in the life sciences industry. Prior to joining Interleukin Genetics, he was Vice President, Finance and Administration and Chief Financial Officer of Nucryst Pharmaceuticals (Nasdaq: NCST, TSX: NCS), where he successfully completed a $45 million IPO within 6 months of joining the company and was responsible for SEC reporting and the implementation of Sarbanes-Oxley requirements. Previously, he served as Chief Financial Officer and Chief Operating Officer for Bridge Pharmaceuticals, Inc., where he established all policies for managing business operations.

Mr. Lurier commented, "I am very excited about the opportunity to join Interleukin Genetics. The Company is well positioned to become a leading provider of preventive consumer products and genetic tests for sale to the emerging personalized health market. I look forward to helping the Company communicate the value of such tests to the investment community."

Prior to joining Bridge Pharmaceuticals, Inc., Mr. Lurier held a number of senior-level financial positions i
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
2. Interleukin Genetics Retains Top Life Science Communications Firms
3. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
6. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
7. Interleukin Genetics Announces Management and Board Appointments
8. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
9. U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
10. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
11. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, Inc. ... treatments for urological and related conditions, announced today that ... private placement convertible note financing, raising a total of ... totaling $3.175 million. Josh Disbrow ... this private placement are intended to be used to ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
(Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Wireless Beat-To-Beat Heart Monitoring and ... ... Inc.,(Nasdaq: BHRT ), announced it has entered into a ... rights to the,POCKETECG, a real-time wireless beat-to-beat, intelligent heart monitor ...
... 1 On the 25th/26th of July the first,ever ... rechts,der Isar" of the Technical University of Munich. The ... Surgery and Hand Surgery. The,operation, performed by a team ... Hohnke (senior physician for Plastic Surgery and Hand Surgery),and ...
... Constant Forex) Substantial Increase in Sales of the ... and key player in the development and,commercialization of molecular diagnostic tests for cancer, today announces,its revenue ... 30 June 2007 30 June 2008 Variation Variation euros)* ... ...
Cached Biology Technology:Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd. 2Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd. 3Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd. 4Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd. 5The First Ever Transplantation World-Wide of Entire Arms at the "Klinikum rechts der Isar" in Munich 2Confirmation of Strong Growth Over the First Half of 2008 2
(Date:8/20/2015)... Aug. 20, 2015   Sensory, Inc ., ... the user experience and security of consumer electronics ... announced that its TrulySecure™ is the ... to be FIDO Certified™. The FIDO ... with the FIDO UAF (Universal Authentication Framework) 1.0 ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
... Engineers at the University of California, Davis, have invented ... microchip fabrication. "The material itself (say, semiconductor wafers) ... Pan, professor of biomedical engineering. He and his fellow ... form a thick layer between two surfaces. Pan,s nanoglue, ...
... [Brown University] In a brief paper in the ... new, freely available Web-based program called Spliceman for predicting ... of messenger RNA, potentially leading to disease. "Spliceman ... and computes how likely these single nucleotide variants alter ...
... is available in German . ... impacts are not over yet, neither in Japan nor ... KIT established working groups that are still processing scientific ... is supporting the energy turnaround in Germany by conducting ...
Cached Biology News:Will a genetic mutation cause trouble? Ask Spliceman 21 year after Fukushima 21 year after Fukushima 3
... Clone/PAD: ZMD.473. Immunogen: Synthetic ... of the mouse junctophilin-2. Specificity: ... Reactivity: Mouse (positive controls: mouse skeletal ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
TGF-beta 2 MAb (Clone 8607)...
UCP1/2/3 (FL-307)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Biology Products: